Evidence map›Paper›PMID 36215572›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Rathan M Subramaniam, Lyudmila DeMora, Min Yao, Sue S Yom, Maura Gillison, Jimmy J Caudell, John Waldron, Ping Xia, Christine H Chung, Minh Tam Truong and 10 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 3 countries.

Rathan M SubramaniamOtago Medical School, University of Otago, Otago, New Zealand; rathan.subramaniam@otago.ac.nz.
Lyudmila DeMoraNRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
Min YaoUniversity Hospitals Cleveland, Cleveland, Ohio.
Sue S YomUniversity of California, San Francisco, California.
Maura GillisonUniversity of Texas MD Anderson Cancer Center, Houston, Texas.
Jimmy J CaudellMoffitt Cancer Center, Tampa, Florida.
John WaldronPrincess Margaret Hospital, Toronto, Oneida, Canada.
Ping XiaCleveland Clinic, Cleveland, Ohio.
Christine H ChungMoffitt Cancer Center, Tampa, Florida.
Minh Tam TruongBoston Medical Center, Boston, Massachusetts.
Michelle EchevarriaMoffitt Cancer Center, Tampa, Florida.
Jason W ChanUniversity of California, San Francisco, California.
Jessica L GeigerCase Western Reserve University, Cleveland, Ohio.
Loren MellUC San Diego Moores Cancer Center, San Diego, California.
Samantha SeawardKaiser Permanente NCI Community Oncology Research Program, Vallejo, California.
Wade L ThorstadWashington University School of Medicine, St. Louis, Missouri.
Jonathan Jay BeitlerEmory University/Winship Cancer Institute, Atlanta, Georgia.
Khalil SultanemJewish General Hospital, Montreal, Canada.
Diagjin BlakajOhio State University Comprehensive Cancer Center, Columbus, Ohio; and.
Quynh-Thu LeStanford University, Stanford, California.
Moffitt Cancer Center · USUniversity of California, San Francisco · USBoston Medical Center · USCase Western Reserve University · USCleveland Clinic · USDuke University · USJewish General Hospital · CAKaiser Permanente Vallejo Medical Center · USNRG Oncology · USPrincess Margaret Cancer Centre · CAStanford University · USThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUC San Diego Health System · USUniversity Hospitals of Cleveland · USWashington University in St. Louis · USWinship Cancer Institute

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3M
OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA180803NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233339
6 · The paper itself

Abstract

The purpose of this study was to determine the negative predictive value (NPV) of a 12- to 14-wk posttreatment PET/CT for 2-y progression-free survival (PFS) and locoregional control (LRC) in patients with p16-positive locoregionally advanced oropharyngeal cancer (LA-OPC). Study was a secondary endpoint in NRG-HN002, a noncomparative phase II trial in p16-positive LA-OPC, stage T1-T2, N1-N2b or T3, N0-N2b, and ≤10 pack-year smoking. Patients were randomized in a 1:1 ratio to reduced-dose intensity-modulated radiotherapy (IMRT) with or without cisplatin.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsChemoradiotherapyFluorodeoxyglucose F18Human Papillomavirus VirusesHumansPositron Emission Tomography Computed TomographyTreatment OutcomeFluorodeoxyglucose F18NRG-HN002p16-positive oropharyngeal cancerPET/CT negative predictive value

Identifiers

PMID36215572
PMCPMC10071810
OpenAlexW4294276818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.